Filing Flows › UroGen Pharma (URGN) › Q3 2025
UroGen Pharma (URGN) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
UroGen Pharma (URGN) reported revenue of $27.5M for the third quarter 2025 (Q3 2025), +9% from a year earlier and +13% from the quarter before. Operating margin was -99.7%, net loss $33.3M (121.3% of revenue).
UroGen Pharma, Q3 2025: revenue $27.5M (+9% year over year), operating margin -99.7%, net loss $33.3M, operating cash flow −$42.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $27.5M | +13% | +9% |
| Operating profit | −$27.4M | — | — |
| Net earnings | −$33.3M | — | — |
| Operating cash flow | −$42.3M | — | — |
What changed
Revenue was $27.5M in Q3 2025, up 9% year over year and up 13% from the previous quarter. Jelmyto was the largest line at 94% of revenue. Jelmyto added $499K year over year (up 2%), 22% of the total change.
Gross margin was 88.1%, down 2.2 points from a year earlier. Operating costs exceeded revenue by $27.4M, an operating margin of -99.7%. Operating expenses grew 28% against revenue growth of 9%. The fastest-growing cost line was SG&A (+30%). The quarter ended with a net loss of $33.3M, narrower than the previous quarter's $49.9M loss.
Operating cash flow was −$42.3M. Non-cash charges added back $100K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $12.1M. Capital expenditures of $87K exceeded it, leaving free cash flow of −$42.4M.
Questions
What was UroGen Pharma's revenue in the third quarter 2025?
UroGen Pharma (URGN) reported revenue of $27.5M for the third quarter 2025 (Q3 2025), +9% from a year earlier and +13% from the quarter before.
Was UroGen Pharma profitable in the third quarter 2025?
Operating loss was $27.4M (-99.7% of revenue) and net loss $33.3M.
Source: UroGen Pharma 10-Q on SEC EDGAR.